Tirzepatide denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Tirzepatide as Experimental

An experimental or investigational denial from Aetna signals that the plan's medical policy has determined — for this specific indication on your claim — that the evidence base does not yet meet its threshold for coverage as established treatment. This can occur when tirzepatide is prescribed for a use that sits at the edge of, or outside, its FDA-approved labeling, or when a plan's policy has not yet been updated to reflect a newer approval.

This denial is frequently appealable because tirzepatide has received FDA approval for defined indications, and if your prescription falls within an approved indication, the experimental classification is challengeable on its face.

## Your Appeal Rights

• ACA §2719 / ERISA §503: Federal law mandates full-and-fair internal review and, if that fails, access to independent external review for most non-grandfathered plans.
• Internal appeal deadline: Typically 180 days from your denial notice; confirm the exact date on your Explanation of Benefits.
• External review window: Approximately four months from the final internal denial to file for independent external review.
• Expedited review: Available when delay would seriously jeopardize your health; request this in writing simultaneously with your internal appeal if applicable.

## Documentation to Gather

1. FDA approval documentation: Print the current FDA label for tirzepatide — specifically the approved indication(s) section — and highlight the indication that matches your prescription. 2. Diagnosis confirmation: Current chart notes confirming your diagnosis aligns precisely with an FDA-approved indication. 3. Relevant guideline organization endorsement: Ask your prescriber to reference whether a major professional society (e.g., the American Diabetes Association, the Obesity Society, or the applicable ACC/AHA guideline) recognizes tirzepatide as a standard treatment option for your condition, without citing specific trial statistics. 4. Prescriber medical-necessity letter: Your physician or advanced practitioner should state, in plain language, that this is not an experimental use — it is on-label, guideline-supported care — and explain why it is necessary for your specific clinical circumstances. 5. Insurer policy mapping: Pull Aetna's current published clinical policy. If the policy's evidence review predates the FDA approval relevant to your indication, note that explicitly in your appeal.

## Criteria-Mapping Structure

Build your appeal around a direct rebuttal of the experimental finding. Structure it as: Aetna's basis for experimental classification (quoted from the denial letter) | Counter-evidence and source | How your case satisfies the established-treatment standard. If the denial letter cites a specific policy version or date, verify whether that policy has been superseded by a newer version that incorporates the current FDA status.

Always verify the current FDA-approved indications in the official prescribing information and review Aetna's most current published clinical policy before submitting your appeal — both may have changed since the denial was issued.